Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/25/2024 | $220.00 | Buy | BTIG Research |
1/12/2024 | $195.00 → $215.00 | Buy | Stifel |
12/19/2023 | $230.00 | Buy | Jefferies |
12/7/2023 | $237.00 | Outperform | Exane BNP Paribas |
9/6/2023 | $230.00 | Buy | HSBC Securities |
7/12/2022 | $205.00 | Overweight | Piper Sandler |
3/9/2022 | $232.00 → $208.00 | Neutral | Citigroup |
12/20/2021 | $184.00 → $232.00 | Neutral | Citigroup |
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
Molson Coors' President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership and board experience, including as a current Chief Executive Officer and former Chief Financial Officer of Molson Coors, to the Zoetis Board. He will serve on the Board's Corporate Governance and Sustainability Committee. "Gavin Hattersley brings invaluable experience to our Board as we continue to expand
Animal welfare nonprofit bolsters board to better serve the needs of pet lovers nationally SAN ANTONIO, Nov. 14, 2023 /PRNewswire/ -- Petco Love welcomes new members to its board of directors, tapping a wide range of expertise to support its lifesaving mission. Petco Love is committed to shared social values and its diverse and inclusive board composition is a significant reflection of the unified values of its communities served nationwide. Since its founding more than 20 years ago, Petco Love excels as a leader and valued partner in animal welfare by creating a better world
Zoetis Inc. (NYSE:ZTS) today announced the addition of Ester Banque as Executive Vice President and President, U.S. Operations, for the company, effective July 10, 2023. Ms. Banque is an accomplished global senior executive with over 30 years of experience in health sciences with top tier pharmaceutical companies. Ester will be a member of the Zoetis Executive team and report to Chief Executive Officer Kristin Peck. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230709430714/en/Ester Banque joins Zoetis as Executive Vice President and President, U.S. Operations, effective July 10, 2023. Source: Zoetis "We are excited to welcome
Reports Revenue of $2.4 Billion, Growing 11%, and Net Income of $682 Million, or $1.50 per Diluted Share, Increasing 14% and 16%, Respectively, on a Reported Basis for Third Quarter 2024 Delivers 14% Operational Growth in Revenue and 15% Operational Growth in Adjusted Net Income for Third Quarter 2024 Reports Adjusted Net Income of $716 Million, or Adjusted Diluted EPS of $1.58, for Third Quarter 2024 Raises Full Year 2024 Revenue Guidance to $9.200 - $9.300 Billion, Representing Operational Revenue Growth of 10% to 11%, with Diluted EPS on an Adjusted Basis of $5.86 to $5.92 Updates Full Year Operational Growth in Adjusted Net Income to 13.5% to 14.5% Zoetis Inc. (NYSE:ZTS)
Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the successful completion of the acquisition of the medicated feed additive product portfolio and certain water-soluble products from Zoetis Inc. (NYSE:ZTS). This acquisition marks a significant step in furthering Phibro's purpose to optimize global animal health and nutrition for better lives and a more sustainable world. "Adding this new lineup of medicated feed additives and water-soluble products across cattle, swine and poultry will complement and expand Phibro's species and product portfolios, helping customers meet the highest standards of animal care, prevent disease, and enhance nutrition around the world," said Jack C
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the fourth quarter of 2024. The dividend will be paid on Tuesday, December 3, 2024, to all holders of record of the Company's common stock as of the close of business on Thursday, October 31, 2024. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and
Reports Revenue of $2.4 Billion, Growing 11%, and Net Income of $682 Million, or $1.50 per Diluted Share, Increasing 14% and 16%, Respectively, on a Reported Basis for Third Quarter 2024 Delivers 14% Operational Growth in Revenue and 15% Operational Growth in Adjusted Net Income for Third Quarter 2024 Reports Adjusted Net Income of $716 Million, or Adjusted Diluted EPS of $1.58, for Third Quarter 2024 Raises Full Year 2024 Revenue Guidance to $9.200 - $9.300 Billion, Representing Operational Revenue Growth of 10% to 11%, with Diluted EPS on an Adjusted Basis of $5.86 to $5.92 Updates Full Year Operational Growth in Adjusted Net Income to 13.5% to 14.5% Zoetis Inc. (NYSE:ZTS)
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the fourth quarter of 2024. The dividend will be paid on Tuesday, December 3, 2024, to all holders of record of the Company's common stock as of the close of business on Thursday, October 31, 2024. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Monday, November 4, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2024 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on November 4, 2024. About Zoetis As the world's leading animal health company, Zoetis is
Across the recent three months, 4 analysts have shared their insights on Zoetis (NYSE:ZTS), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Zoetis, presenting an average target of $205.25, a high estimate of $225.00, and a low estimate of $180.00. A negative shift in sentiment
BTIG analyst Mark Massaro initiates coverage on Zoetis (NYSE:ZTS) with a Buy rating and announces Price Target of $220.
Zoetis (NYSE:ZTS) has outperformed the market over the past 10 years by 7.71% on an annualized basis producing an average annual return of 18.4%. Currently, Zoetis has a market capitalization of $81.78 billion. Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $5,424.03 today based on a price of $179.23 for ZTS at the time of writing. Zoetis's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
10-Q - Zoetis Inc. (0001555280) (Filer)
8-K - Zoetis Inc. (0001555280) (Filer)
8-K - Zoetis Inc. (0001555280) (Filer)
BTIG Research initiated coverage of Zoetis with a rating of Buy and set a new price target of $220.00
Stifel reiterated coverage of Zoetis with a rating of Buy and set a new price target of $215.00 from $195.00 previously
Jefferies resumed coverage of Zoetis with a rating of Buy and set a new price target of $230.00
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species. Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o